Gerard_ecb schreef op 27 april 2017 08:23:
Om aan alle discussie een einde te maken hier het antwoord van ir. Overigens wat een transparant bedrijf top! Net verstuurd en 10 minuten later het antwoord.
The deal is a royalty buy-out combined with a collaboration agreement. The $15 million included payments accrued since negotiation for the patents began in July 2016. We will not be receiving any additional royalty or milestone payments.
Per Exact Sciences’s prior communications, it had commenced steps with the intention to replace our NDRG4 biomarker with a new methylation marker in Cologuard. Exact Sciences was receptive to an agreement. It is clear from their investor materials that they have a renewed focus on R&D efforts for their second test for lung cancer, and would prefer to allocate internal resources to this. To that end, MDxHealth and Exact Sciences have also entered into a five-year R&D collaboration agreement that has potential upside that may exceed the benefits of the biomarker and technology licenses alone.
As you already know, MDxHealth and Exact are industry-leading companies in epigenetic-powered diagnostics worldwide and each has been investing 10’s-of-millions in new discovery and development programs. Each has a portfoiio of cutting edge epigenetic and other molecular diagnostics biomarkers and technologies in a range of indications. The partners are focused on different markets:
o Exact: (1) Colon, Lung and (2) Screening (asymptomatic)
o MDxHealth (1) Urologic and (2) Diagnostics (symptomatic), monitoring, PharmacoMDx
We believe the royalty buy-out combined with a collaboration agreement is the most optimal outcome for both parties.